Explore small cap ideas before they hit the headlines.
Explore small cap ideas before they hit the headlines.
I thought there was a limit on how many Reverse Splits a POS ticker can do before they go to the pinks where they belong.
This one has had 5 since Oct 2024 - NASDAQ IS ABSOLUTELY THE PLACE FOR SHIT TICKERS THESE DAYS - ZERO STANDARDS OR PROTECTIONS FOR SHAREHOLDERS.
Yeah, it doesn't take a committee to figure out $10.75 is a huge win from 13 cents and very little "evaluation" is required.
I'll need to be " contained / restrained " if they F this up ...:--)
Always assume they F this up and be pleasantly surprised if they somehow pull it off.
JMHO
I would like the warrants to start reflecting how well the commons are doing.
Last I read was the offer at $10.25 or .75 and formation of evaluation committee.
I NEVER DIVE TO DEEP SO I CAN'T BE HURT BADLY.
But I understand these massive drops do not generally turn out well.
Time will tell
OT- Right or wrong I just let my URGN go at 770% - sorry it just had to be done
Bought @ $3.69 in May of 2025
Bought in @ $2.64 just over 2 years ago in May of 2024 - no complaints
Where do you see that Chumley? Or you just talkin shite?
This turd broke under $2 - on the expressway to double digits with a final destination of single digits that just how much of a scam it is BUT WAIT STICK AROUND AND JOIN IN THE FUN OF THEIR NEXT REVERSE SPLIT TO LOOK LIKE AN ACTUAL COMPANY NOT A NAPLES SCAM TICKER
GSIT making an impressive move this morning.
Catch any of the .12s
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: H.C. Wainwright 4th Annual BioConnect Investor Conference
Date: May 19, 2026
Event: Jefferies Global Healthcare Conference
Date: June 2-4, 2026
Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Yup, nothing objectionable - Yes across the board.
There ya go 760
It was strange, only got partial fills in 7 different accounts - 3200 shares - the orders remain active in case someone else wants to throw away their shares.
Caught some .12s today.
Thanks for trying to save me, I've only been playing this game since 2009.
I'll let you know if they sell - 2 years to expiration gives it lot of time to get it's sht together.
I'm never ashamed of putting anything I hold up for sale - never know if they somehow get out of the Expert Market and like I said - they are there for anyone who may want them. Either way they are sitting in my account so why not throw a number on 'em to sell?
I can't buy but I have my CPTWF up for sale at a nickel.
It costs me nothing until they sell IF they sell.
It doesn't cost that much to be listed on OTCMarkets. Only reason to remain silent is because there is absolutely zero value in anything they say.
They need to get their sht together and get off Expert Market if they have any value at all.
I followed you back, when I have time I'm gonna look at the tickers you like to see if I find anything INTERESTING to bet on.
Meet the micro-cap biotech company reinventing regenerative medicine
May 07 2026 - 12:18PM
IH Market News
It’s a well-known and almost quaint fact that the human body is capable of regeneration. When we suffer a minor scrape or a cut, a little disinfectant, a band-aid and a few days is all it usually takes to be as good as new.
But the body’s regenerative powers are not evenly distributed. Skin, blood and certain tissues can repair themselves relatively well, while the central nervous system, including the brain, spinal cord and optic nerve, is a much more difficult frontier. Once neurons and their connections are severely damaged, the body has limited ability to rebuild them on its own, leaving patients at risk of permanent losses in movement, sensation or vision.
This is why the field of regenerative medicine is focused on ways to help the body replace or repair diseased or damaged cells through stem cells, monoclonal antibodies and even electrical stimulation. Over the past 60 years, advances such as the first bone marrow transplant in 1968 have helped catalyze this field.
That said, stem-cell-based regenerative medicine still faces major hurdles. Living-cell therapies are difficult to manufacture consistently, reproduce from batch to batch, store and scale. They may also face donor variability, immune compatibility issues, poor survival or integration after administration, and safety concerns such as unwanted differentiation or tumorigenicity in certain settings. These limitations help explain the growing interest in acellular regenerative approaches designed to capture the signaling benefits of cells without using the cells themselves.
These limitations create a significant opportunity within the US$35 billion global regenerative medicine market, which is expected to grow by more than 150 per cent to US$90 billion by 2030. There is a lucrative pathway for biotech companies to innovate and usher the field into its next era of growth.
Introducing NurExone Biologic
One company taking up this challenge head on is NurExone Biologic (TSXV:NRX) (USOTC:NRXBF), market cap C$50.63 million, with ample early-stage preclinical evidence in support of its exosome-based therapies as treatments for central nervous system injuries, including spinal cord and optic nerve injuries, with treatment associated with improvements in functional and sensory recovery after a short treatment cycle.
This article is disseminated in partnership with NurExone Biologic Inc. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Exosomes are cell-secreted nanoparticles that may naturally home to inflamed or damaged tissue and hold potential for wide-ranging applications in wound healing and nerve growth, including aesthetic use-cases spanning skin rejuvenation, hair growth and anti-aging in a market expected to 10x over the next decade. The benefits of exosomes versus stem cells include:
No living cells – Exosome-based therapies are acellular, which may reduce certain safety, immune, and compatibility concerns associated with cell-based therapies.
Scalability – Easier and larger-batch production using 2D and 3D reactors, both of which are part of NurExone’s production process.
Storage and Handling – Exosomes can potentially be frozen and thawed without losing effectiveness. This may simplify storage, handling, and supply-chain requirements compared with living stem cells.
Minimally invasive administration, given exosomes’ affinity for distressed tissue, they support less invasive treatment approaches.
NurExone is developing its proprietary ExoTherapy platform to capitalize on exosomes’ healing and regenerative properties, deploying in-house capabilities to produce the nanoparticles, synthesize therapeutic cargo, load that cargo onto the nanoparticles and develop them into nanodrugs for testing and potential commercialization. The company has a handful of strategic unmet needs in its sights, each of which is tied to a multi-billion-dollar market.
ExoPTEN for acute spinal cord injuries
NurExone’s first nanodrug, ExoPTEN, uses as its cargo a proprietary RNA sequence to inhibit the expression of the PTEN tumor-suppressor gene, commonly found in neurons and regenerating axons, with numerous studies showing that PTEN inhibition can promote wound repair and nerve growth after injury.
ExoPTEN’s first targeted use-case is the regeneration of spinal neurons, vying to improve quality of life for the more than 900,000 new traumatic spinal cord injury patients per year representing a US$7.9 billion opportunity to ease the strain on the global healthcare system.
The drug is the first known minimally invasive therapy shown to foster nerve regeneration following a full spinal cord transection in preclinical studies. About 75 per cent of animals in the study recovered motor function and results were replicated across multiple experiments in NurExone’s labs. While monoclonal antibodies and epidural electrical stimulation can be developed into non-immunogenic, off-the-shelf products, they have not demonstrated the ability to repair a full spinal cord transection making ExoPTEN a comparatively better candidate for a new standard of care in the regenerative medicine landscape.
ExoPTEN’s promising, early-stage evidence led the US Food and Drug Administration and the European Medicines Agency to award it the Orphan Drug Designation for acute spinal cord injuries, granting NurExone potential benefits including fee reduction, an expedited clinical process, as well as 7-12 years of market protection, reinforcing the company’s pathway to clinical trials in the US and Europe.
With millions of people with spinal cord injuries standing to benefit from better treatment options, NurExone is pursuing Investigational New Drug status with the US FDA, keen to kick off phase-1 human trials in 1H 2027 and further demonstrate how its stock price is a poor reflection of the ExoTherapy platform’s clinical and commercial potential.
ExoPTEN for acute glaucoma
NurExone is also studying ExoPTEN as a therapy to treat acute glaucoma, a disease that damages the optic nerve, putting vision at risk for 350,000-700,000 new people every year. With vision loss and blindness costing the US about US$26,900 per patient annually, this equates to a more than US$9 billion opportunity, robustly incentivizing innovators like NurExone to step in and solve this global health burden.
The company has also delivered successful pre-clinical results under this indication, substantiating optic nerve healing and vision restoration in 75 per cent of animals in a study.
A larger-scale pre-clinical study is currently underway at the Sheba Medical Center, ranked as the 8th best hospital in the world by Newsweek in 2025, which will support a phase-I clinical trial envisioned for the first half of 2027.
NurExone leadership has taken its future into its own hands by establishing a US subsidiary to anchor a push into the North American market.
Exo-Top
Exo-Top, NurExone’s wholly owned US subsidiary, will lead the company’s North American manufacturing, development and commercialization strategy, harnessing a Master Cell Bank of GMP-grade human bone marrow mesenchymal stem cells (MSC) – as a foundation for exosome production, ensuring consistency during the transition from the preclinical to the commercial realm.
The US subsidiary, focused on production and supply, will work in close proximity with NurExone Biologic Ltd., tasked with R&D and product development. Exo-Top is expected to leverage a sublicense agreement that gives it biomanufacturing rights to the technology underlying the ExoTherapy platform.
Fantastic news out today and crickets.... very strange even for Ihub
Divi for 1st quarter of .0157 for owners as of May 20th - pay date is June 1st.
NOT BAD FOR A 40 CENT TICKER
Nothing I can do, I own the commons and the warrants so all I can do is hope they are able to fall azz backwards into the money somehow.
Added on the offering smackdown.
The purpose of this letter and the enclosed Information Statement is to inform you that stockholders holding shares of Series A Convertible Preferred
Stock (the “Series A Preferred”) and shares of Common Stock, representing in excess of a majority of the outstanding shares of Common Stock of American
Rebel Holdings, Inc. (“American Rebel”) have executed a written consent dated April 8, 2026 (the “Written Consent”) in lieu of a special meeting to
effectuate the following: to (i) authorize up to a 1-for-250 reverse stock split of American Rebel’s Common Stock (the “Reverse Stock Split”), (ii) in
connection therewith, approve an amendment to American Rebel’s Second Amended and Restated Articles of Incorporation to effectuate the Reverse Stock
Split, and (iii) authorize any other action deemed necessary to effectuate the Reverse Stock Split, without further approval or authorization of American Rebel
stockholders, at any time within 12 months of the approval of this action (the “Action”).
I understand what you are saying but in this case it is a matter of piss poor management or frauds if you will.
They did a 100 to 1 RS in March and now the drunkards are planning another RS - THIS IS A SCAM TICKER NO MATTER WHAT KIND OF BS THEY PUT OUT.
They are not one day closer to having audited fins then they were in November of last year. BUT it's almost time for the regurgitation of their classic line of BS.
The 100 to 1 RS isn't even 2 months old and it looks like this piss water maker is ready to do it again. Free vasoline for existing shareholders about to get it in the azz again.
Still a criminal operation. NO BUSINESS - NO SALES - NO PRODUCT but the 3 scammers pull in $10.5mIL per year in "compensation"... FOR WHAT IT HAS ALWAYS BEEN A SCAM ONLY THE SCAMMERS CHANGE ON THIS TURD TICKER
I know nobody wants to hear this but I will put it out there anyway.
I think the price target is wayyyy too high, using simpleton view I think this may touch $11 on approval before the company does something stupid to drop it from there, remember I don't get emotional about stocks I just use my own valuation metrics or ideas. If this was headed to $22 it would already be over $15 this close to PDUFA date, it has always spiked months before on any bio I own. This one really hasn't moved all that much when you factor in the 10 to 1 RS this basically is a 75 cent stock - sorry some call me crazy but it makes sense in my wacko head.
MAY I BE 100% WRONG, I HOPE I AM
Never heard of B Riley? I own it
IDK but it all looks good to me.
“We are pleased to highlight that deeper analyses of the sunRIZE outcomes and ongoing observations from the extension phase of the study consistently indicate evidence of target engagement, drug activity, and the potential for meaningful therapeutic benefit from ersodetug,” said Brian Roberts, M.D., Chief Medical Officer of Rezolute. “These results underscore our confidence in the potential of ersodetug to transform the HI treatment landscape and embolden our mission to achieve alignment with FDA on an acceptable path to approval in this indication, so that we can keep delivering ersodetug to patients and families living with congenital HI.”
Yeah, you are heavily invested in UNCY - personally I don't have that much faith in any stock.
It looks like you have a lot of company in UNCY getting approved.
I'll make money but not enough to scream about but gains are gains.
I completely understand your position as you entered the warrants wayyyy higher than myself, I hate when they go bad.
This one was sketchy and has turned into a nightmare for many. Imagine the peeps who bought commons at $6 and above - YIKES scary
I already own OSTX. I started a position in PMI in all 8 accounts. Not large chucks but small opening positions.
I believe in artificial hearts and I like their idea of a totally implantable one in the future.
I'm a gambler, I'm still up 793% on the warrants, I'm in it to win it